According to the study from Li et al., SGLT2 inhibitors can significantly reduce the likelihood of serious adverse events (SAEs) in AF (risk ratio: 0.83; 95% confidence interval 0.71–0.96) (38). The gene discussed is SLC5A2; the disease is atrial fibrillation.